Jonathan Fletcher, MD Chief Scientific Officer, SARC Harvard Medical School, Brigham and Women’s Hospital, Dana-Farber Cancer Institute Dr. Jonathan Fletcher is a lab-based medical and pediatric oncologist and geneticist at Harvard Medical School, Brigham and Women’s Hospital, and Dana-Farber Cancer Institute. His lab focus is translational GIST and sarcoma research, where the main priority is to identify and validate novel therapeutic strategies. His research program has discovered oncogenic mechanisms in GIST and many sarcoma subtypes. By developing novel genomic and phospho-protein screens, his group identified the first FGFR1 and PDGFRA oncoproteins and the first ALK oncoproteins in solid tumors. They have advanced new models and biologic insights for GIST, leiomyosarcoma, MPNST, liposarcoma and endometrial stromal sarcoma, among others. His group performed preclinical validations and correlative science supporting the FDA-approved drug applications for GIST, and he coordinates international research consortia devoted to maximizing therapeutic response in GIST and leiomyosarcoma. Dr. Fletcher co-founded CTOS and founded and co-leads SASS, an annual SARC/NCI workshop for sarcoma basic science. He also chairs the clinical trial selection committee of the National Center for Tumor Diseases / Germany and is co-PI for an NCI SPORE grant on LMS and other “complex” sarcomas. Dr. Fletcher’s clinical activities are in cancer diagnostics, with a focus on molecular cytogenetics. Fletcher chairs the SARC Scientific Steering and Discovery/Translation committees, and he was appointed SARC Chief Scientific Officer in July, 2021.